

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q94746

Frederick W. HARTNER, et al.

Appln. No.: 10/578,476

Group Art Unit: 1625

Confirmation No.: 8989

Examiner: Not Yet Assigned

Filed: May 8, 2006

For: PROCESSES FOR PREPARING BICYCLO [3.1.0] HEXANE DERIVATIVES, AND  
INTERMEDIATES THERETO

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT  
U.S. Appln. No.: 10/578,476

Q94746


filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Applicant submits that the listed documents are cited and discussed on pages 1 and 3 of the specification of the present application.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

  
\_\_\_\_\_  
Susan J. Mack  
Registration No. 30,951

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
**23373**  
CUSTOMER NUMBER

Date: November 17, 2006

Substitute for Form 1449 A & B/PTO				<i>Complete if Known</i>	
<b><u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u></b>				Application Number	10/578,476
				Confirmation Number	8989
				Filing Date	May 8, 2006
				First Named Inventor	Frederick W. HARTNER
				Art Unit	1625
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	Q94746

## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		JOHN W. MCDONALD ET AL: "Physiological and pathophysiological roles of excitatory amino acids during central nervous system development", Brain Research Reviews, U.K., vo. 15, no. 1, pp. 41-70, January-April, 1990.	
		DARRYLE SCHOEPP ET AL: "Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors", EAA Pharmacology, TiPS, U.K., vol. 11, pp. 508-515, December 1990.	
		ATSURO NAKAZATO ET AL: "Synthesis, SARs, and Pharmacological Characterization of 2-Amino-3 or 6-fluorobicyclo[3.1.0] hexane-2,6-dicarboxylic Acid Derivatives as Potent, Selective, and Orally Active Group II Metabotropic Glutamate Receptor Agonists" American Chemical Society, J. Med. Chem. 2000, 43, pp. 4893-4909.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.